Tumor-suppressive effects of SPOP in prostate cancer, where it acts as a negative regulator of BET protein stability, and also provides a molecular mechanism for resistance to BET inhibitors in individuals with prostate cancer carrying SPOP mutations (281). This evidence concerns the gene SPOP and prostate cancer.